Tempus xM MRD

Tumor-naïve MRD assay for ctDNA detection

xM MRD is a liquid-only approach to MRD assessment that detects trace amounts of residual ctDNA, leveraging both methylation and genomic variant MRD classifiers while applying algorithms that support filtering of artifacts, like CHIP and germline variants, to deliver a binary MRD call.

As a tumor-naïve assay with dual workflows, Tempus xM MRD offers several advantages to biopharma, including accelerated turnaround times as well as the availability of variant-level information. xM MRD is currently available in stage II-III colorectal cancer. Tempus is actively seeking partners for indication expansion for this assay.

SOPHISTICATED MRD MODEL

Harnessing the power of a dual workflow

xM MRD leverages both variant and methylation workflows to call MRD+/-, bringing forward variant-level data about your patient cohort.*

Faster TAT

As a tumor-naïve assay, xM MRD reduces operational research delays due to tissue procurement.

Data-informed model

The xM MRD algorithmic model was developed using Tempus’ robust multimodal database, leveraging known tumor profiles and clinical outcomes to correct for CHIP and germline confounders.

Valuable insights with every sample

xM MRD utilizes both methylation and variant workflows to call MRD+/-, helping to bring forward variant level data on cohorts.*

Our Science

Longitudinal clinical performance of a novel tumor-naïve minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-Japan

xM MRD results predict disease-free survival (DFS) nearly 5 times superior to standard of care carcinoembryonic antigen (CEA) (adjusted hazard ratio 9.69 vs. 2.13).

LEARN MORE

Partnership Opportunities

Strategic validation studies with flexible opportunities for additional indications

Colorectal Cancer (CRC)

Tempus xM MRD is clinically validated¹ for early stage (II and III) colorectal cancer and reports on robust variant gene data specific to this indication.

Custom models

For indications outside of colorectal cancer, we are excited to collaborate with biopharma partners and build custom models.

ctDNA Suite

Tempus offers a comprehensive liquid portfolio to support drug development, including patient stratification for future trials, clinical trial design, and treatment response monitoring. Tempus xM Monitor (ctDNA tumor fraction calculation & monitoring) is currently available for biopharma partners for research use only.

TEMPUS xM MRD

MRD Detection

A tumor-naïve assay that detects ctDNA in patients following curative-intent treatment to identify patients at high risk of recurrence. Currently available in early stage (II and III) colorectal cancer.
LEARN MORE
TEMPUS xM MONITOR

ctDNA Tumor Fraction Calculation and Monitoring

A ctDNA assay which measures changes in ctDNA tumor fraction to provide information on early response to immunotherapy for patients with advanced cancers. Currently available for research use only.
LEARN MORE
TEMPUS xF+

523 Gene Liquid Assay

A ctDNA seq panel that interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help clinicians identify treatment opportunities. Identifies SNV, insertions / deletions, CNVs, gene rearrangements from select genes, as well as MSI and bTMB.
LEARN MORE
TEMPUS xF

105 Gene Liquid Assay

A ctDNA seq panel that detects oncogenic drivers and resistance mutations, assesses for MSI, and identifies SNVs, INDELs, and CNVs.
LEARN MORE

MRD Detection

A tumor-naïve assay that detects ctDNA in patients following curative-intent treatment to identify patients at high risk of recurrence. Currently available in early stage (II and III) colorectal cancer.

LEARN MORE

ctDNA Tumor Fraction Calculation and Monitoring

A ctDNA assay which measures changes in ctDNA tumor fraction to provide information on early response to immunotherapy for patients with advanced cancers. Currently available for research use only.

LEARN MORE

523 Gene Liquid Assay

A ctDNA seq panel that interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help clinicians identify treatment opportunities. Identifies SNV, insertions / deletions, CNVs, gene rearrangements from select genes, as well as MSI and bTMB.

LEARN MORE

105 Gene Liquid Assay

A ctDNA seq panel that detects oncogenic drivers and resistance mutations, assesses for MSI, and identifies SNVs, INDELs, and CNVs.

LEARN MORE

1 Nakamura, Y., et al. A tumor-uninformed ctDNA assay detecting MRD in patients with resected stage II or III colorectal cancer predicts recurrence: Subset analysis from the GALAXY study in CIRCULATE-Japan. Presented at ASCO GI 2024.

*Dual methylation and variant workflows are utilized at the landmark timepoint (LMT) only, all subsequent timepoints utilize the methylation workflow only.

This is data-driven precision medicine

This is the future of healthcare.